Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Biocartis Group NV    BCART   BE0974281132

BIOCARTIS GROUP NV

(BCART)
  Report
Real-time Quote. Real-time Euronext Bruxelles - 01/15 11:35:08 am
4.7 EUR   -0.63%
01/11BIOCARTIS : Meets 2020 key objectives
PU
01/11PRESS NEWS BIOCARTIS GROUP NV : Biocartis meets 2020 key objectives
AQ
2020BIOCARTIS : Disclosure of outstanding voting securities
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Press news Biocartis Group NV - Regulated Information : Disclosure of a transparency notification

11/24/2020 | 01:00am EST

PRESS RELEASE - REGULATED INFORMATION

24 November 2020, 07:00 CET

Disclosure of a transparency notification

Mechelen, Belgium, 24 November 2020Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the ‘Belgian Transparency Act’), that on 19 November 2020 it received a transparency notification dated 19 November 2020 (the ‘Notification’), indicating that on that date the shareholding of Debiopharm Innovation Fund S.A. decreased below the 3% notification threshold. Debiopharm Innovation Fund S.A. now holds 2.95% of the voting rights in Biocartis.

The Notification contains the following information:

  • Reason for the Notification: Acquisition or disposal of voting securities or voting rights, and downward crossing of the lowest threshold.
     
  • Notification by: A parent undertaking or a controlling person.
     
  • Person subject to the notification requirement: Debiopharm Innovation Fund S.A., Chemin Messidor 5-7, 1006 Lausanne, Switzerland; Après-Demain S.A. (formerly Après-Demain Holding S.A.), Chemin Messidor 5-7, 1006 Lausanne, Switzerland; Thierry Mauvernay, Chemin du Praz-Buchilly 113, 1000 Lausanne 25, Switzerland.
     
  • Transaction date: 19 November 2020.
     
  • Threshold that is crossed: 3%.
     
  • Denominator: 56,382,088.
     
  • Details of the Notification: Debiopharm Innovation Fund S.A. now holds 1,662,963 voting securities.
     
  • Chain of controlled undertakings through which the holding is effectively being held: Debiopharm Innovation Fund S.A. is controlled by Après-Demain S.A. (formerly Après-Demain Holding S.A.), which is controlled by Mr. Thierry Mauvernay.

For further information, reference is made to the Notification which is available here on the Biocartis website.

Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (‘FSMA’) is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

--- END ---


More information:
Renate Degrave
Head of Corporate Communications & Investor Relations Biocartis
e-mail   rdegrave@biocartis.com
tel         +32 15 631 729
mobile   +32 471 53 60 64

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for SARS-CoV-2 and sepsis. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.

Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Attachment

  • 20201119 DPIF tr-1be-ENG_FINAL

© OMX, source OMX

All news about BIOCARTIS GROUP NV
01/11BIOCARTIS : Meets 2020 key objectives
PU
01/11PRESS NEWS BIOCARTIS GROUP NV : Biocartis meets 2020 key objectives
AQ
2020BIOCARTIS : Disclosure of outstanding voting securities
PU
2020PRESS NEWS BIOCARTIS GROUP NV : Disclosure of outstanding voting securities
AQ
2020PRESS NEWS BIOCARTIS GROUP NV : Biocartis Announces the Conversion of EUR 15 mil..
AQ
2020BIOCARTIS : Disclosure of a transparency notification
PU
2020PRESS NEWS BIOCARTIS GROUP NV - REGU : Disclosure of a transparency notification
AQ
2020BIOCARTIS : Announces Publication of Large Multi-Center Comparison Study with Id..
PU
2020PRESS NEWS BIOCARTIS GROUP NV : Biocartis Announces Publication of Large Multi-C..
AQ
2020BIOCARTIS : Announces Ten Idylla™ Studies to be Published at Virtual AMP (..
PU
More news
Financials
Sales 2020 44,5 M 53,7 M 53,7 M
Net income 2020 -56,7 M -68,5 M -68,5 M
Net Debt 2020 105 M 126 M 126 M
P/E ratio 2020 -4,41x
Yield 2020 -
Capitalization 270 M 327 M 327 M
EV / Sales 2020 8,43x
EV / Sales 2021 7,25x
Nbr of Employees 499
Free-Float 83,6%
Chart BIOCARTIS GROUP NV
Duration : Period :
Biocartis Group NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCARTIS GROUP NV
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 7,67 €
Last Close Price 4,70 €
Spread / Highest target 91,5%
Spread / Average Target 63,1%
Spread / Lowest Target 38,3%
EPS Revisions
Managers and Directors
NameTitle
Herman Verrelst Chief Executive Officer & Executive Director
Christian Reinaudo Independent Chairman
Piet Houwen Chief Operating Officer
Jean-Marc Roelandt Chief Financial Officer
Benoit Devogelaere Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
BIOCARTIS GROUP NV1.08%327
NOVOCURE LIMITED-3.17%17 056
MASIMO CORPORATION-2.61%14 390
ASAHI INTECC CO., LTD.-7.57%8 740
PENUMBRA, INC.30.55%8 296
GETINGE AB1.72%6 356